S Abad1, D Monnet, S Caillat-Zucman, S Mrejen, P Blanche, M Chalumeau, L Mouthon, R Dhote, A P Brézin. 1. Service de Médecine Interne, Laboratoire de recherche clinique et thérapeutique UPRES EA3409, Université Paris XIII, Faculté Léonard de Vinci, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Paris, France. sebastien.abad@avc.ap-hop-paris.fr
Abstract
PURPOSE: To assess in patients followed in a French referral center the clinical spectrum of Vogt-Koyanagi-Harada (VKH) disease and the HLA-DRB1*04 genotype. METHODS: Patients previously diagnosed as having VKH disease were re-evaluated in a cross-sectional study using the VKH Committee's revised criteria. High-resolution HLA-DRB1 genotyping was performed. RESULTS: Eleven white patients satisfied ophthalmologic diagnostic criteria. All originated from Mediterranean countries. Nine and 3 patients had neurologic and/or cutaneous abnormalities, respectively. Among DRB1*04-positive patients, the HLA-DRB1*0405 subtype was 71%. CONCLUSION: These VKH patients predominantly had an incomplete form. The HLA-DRB1*0405 subtype allele was enriched in a group of Mediterranean stock.
PURPOSE: To assess in patients followed in a French referral center the clinical spectrum of Vogt-Koyanagi-Harada (VKH) disease and the HLA-DRB1*04 genotype. METHODS:Patients previously diagnosed as having VKH disease were re-evaluated in a cross-sectional study using the VKH Committee's revised criteria. High-resolution HLA-DRB1 genotyping was performed. RESULTS: Eleven white patients satisfied ophthalmologic diagnostic criteria. All originated from Mediterranean countries. Nine and 3 patients had neurologic and/or cutaneous abnormalities, respectively. Among DRB1*04-positive patients, the HLA-DRB1*0405 subtype was 71%. CONCLUSION: These VKHpatients predominantly had an incomplete form. The HLA-DRB1*0405 subtype allele was enriched in a group of Mediterranean stock.
Authors: K Diallo; S Revuz; G Clavel-Refregiers; T Sené; C Titah; M Gerfaud-Valentin; P Seve; R Jaussaud Journal: BMC Ophthalmol Date: 2020-10-07 Impact factor: 2.209